Epitopea

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea's CryptoMap platform.

RNA medicine enters its second act By Joachim Eeckhout, June 11, 2026 INNOVATION The COVID-19 pandemic trans- formed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of de

Epitopea has confirmed the Institute of Cancer Research Professor in Women's Cancers, Susana Banerjee, as chief investigator of the OVACT trial.

MHRA approves clinical trial for ovarian cancer therapy By Bruno Quinney, April 24, 2026 The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovari

Epitopea wins UK approval for therapeutic vaccine trial By Uta Mommert, April 23, 2026 CryptiVax-1001 is set to enter first-in-human testing in advanced high-grade serous ovarian cancer, a setting with few durable treatment options. Epitopea has received

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-t

Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, UK and MONTREAL, CANADA, 23 April 2026 - Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, tod

CAMBRIDGE, UK and MONTREAL, CANADA, 13 April 2026 - Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors, today announced the appointment of Lisa Butterfi

GlobeNewswire Press Release.